1. F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA. (1st April 2018) Authors: Davis, Robert; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Vanover, Kimberly Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA. (1st April 2018) Authors: Davis, Robert; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Vanover, Kimberly Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY. (1st April 2018) Authors: Vanover, Kimberly; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Davis, Robert Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S341 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P2‐032: ITI‐007 (LUMATEPERONE) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA, INCLUDING ALZHEIMER'S DISEASE. (1st July 2006) Authors: Satlin, Andrew; Vanover, Kim; Glass, Steven; Saillard, Jelena; Mates, Sharon; Weingart, Michal; Davis, Robert E. Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 12 Page Start: P678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S35. THE PLACEBO CONUNDRUM: MITIGATING THE RESPONSE AT THE SITE LEVEL. (18th May 2020) Authors: Hassman, Howard; Cohen, Elan; Walling, David; Wyka, Katarzyna; Grindell, Vera; Glass, Steven; Ball, Roberta; Styczynski, John; Lobb, Jaclyn; Hazzard, Dakota; Joseph, Ashok; Ereshefsky, Larry Journal: Schizophrenia bulletin Issue: Volume 46(2020)Supplement 1 Page Start: S45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S117. FAVORABLE LONG-TERM SAFETY PROFILE OF LUMATEPERONE IITI-007): RESULTS FROM A 12 MONTH OPEN LABEL SAFETY STUDY FOR LUMATEPERONE IN PATIENTS WITH STABLE SYMPTOMS OF SCHIZOPHRENIA. (9th April 2019) Authors: Vanover, Kimberly; Satlin, Andrew; Durgam, Saresh; Weingart, Michal; Saillard, Jelena; Sanchez, Juan; Hossain, Shawon; Glass, Steven; Kozauer, Susan; Mates, Sharon; Davis, Robert Journal: Schizophrenia bulletin Issue: Volume 45(2019)Supplement 2 Page Start: S351 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study. (12th March 2019) Authors: Vanover, Kimberly; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Sanchez, Juan; Weingart, Michal; Mates, Sharon; Satlin, Andrew; Davis, Robert Journal: CNS spectrums Issue: Volume 24:Number 1(2019:Feb) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗